Literature DB >> 25179581

Early allograft dysfunction in liver transplantation with donation after cardiac death donors results in inferior survival.

David D Lee1, Amandeep Singh, Justin M Burns, Dana K Perry, Justin H Nguyen, C Burcin Taner.   

Abstract

Donation after cardiac death (DCD) liver allografts have been associated with increased morbidity from primary nonfunction, biliary complications, early allograft failure, cost, and mortality. Early allograft dysfunction (EAD) after liver transplantation has been found to be associated with inferior patient and graft survival. In a cohort of 205 consecutive liver-only transplant patients with allografts from DCD donors at a single center, the incidence of EAD was found to be 39.5%. The patient survival rates for those with no EAD and those with EAD at 1, 3, and 5 years were 97% and 89%, 79% and 79%, and 61% and 54%, respectively (P = 0.009). Allograft survival rates for recipients with no EAD and those with EAD at 1, 3, and 5 years were 90% and 75%, 72% and 64%, and 53% and 43%, respectively (P = 0.003). A multivariate analysis demonstrated a significant association between the development of EAD and the cold ischemia time [odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.01-1.56, P = 0.037] and hepatocellular cancer as a secondary diagnosis in recipients (OR = 2.26, 95% CI = 1.11-4.58, P = 0.025). There was no correlation between EAD and the development of ischemic cholangiopathy. In conclusion, EAD results in inferior patient and graft survival in recipients of DCD liver allografts. Understanding the events that cause EAD and developing preventive or early therapeutic approaches should be the focus of future investigations.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25179581     DOI: 10.1002/lt.23985

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

1.  The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation.

Authors:  Tang Yunhua; Ju Weiqiang; Chen Maogen; Yang Sai; Zhang Zhiheng; Wang Dongping; Guo Zhiyong; He Xiaoshun
Journal:  J Clin Monit Comput       Date:  2017-08-22       Impact factor: 2.502

2.  Long Cold Ischemia Times in Same Hospital Deceased Donor Transplants.

Authors:  Eric K Chow; Sandra DiBrito; Xun Luo; Corey E Wickliffe; Allan B Massie; Jayme E Locke; Sommer E Gentry; Jacqueline Garonzik-Wang; Dorry L Segev
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

3.  Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model.

Authors:  Vatche G Agopian; Michael P Harlander-Locke; Daniela Markovic; Wethit Dumronggittigule; Victor Xia; Fady M Kaldas; Ali Zarrinpar; Hasan Yersiz; Douglas G Farmer; Jonathan R Hiatt; Ronald W Busuttil
Journal:  JAMA Surg       Date:  2018-05-01       Impact factor: 14.766

Review 4.  Conceptual changes in small-for-size graft and small-for-size syndrome in living donor liver transplantation.

Authors:  Toru Ikegami; Jong Man Kim; Dong-Hwan Jung; Yuji Soejima; Dong-Sik Kim; Jae-Won Joh; Sung-Gyu Lee; Tomoharu Yoshizumi; Masaki Mori
Journal:  Korean J Transplant       Date:  2019-12-31

Review 5.  Liver transplantation: Current status and challenges.

Authors:  Caroline C Jadlowiec; Timucin Taner
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Authors:  Karen L Thomsen; Francis P Robertson; Peter Holland-Fischer; Brian R Davidson; Rajeshwar P Mookerjee; Holger J Møller; Rajiv Jalan; Henning Grønbæk
Journal:  J Clin Exp Hepatol       Date:  2018-10-05

Review 7.  The therapeutic potential of exosomes derived from different cell sources in liver diseases.

Authors:  Yun Pan; Wei-Feng Tan; Mu-Qing Yang; Ji-Yu Li; David A Geller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-02-02       Impact factor: 4.052

8.  A two-circular RNA signature of donor circFOXN2 and circNECTIN3 predicts early allograft dysfunction after liver transplantation.

Authors:  Kun Wang; Xuyong Wei; Qiang Wei; Di Lu; Wangyao Li; Binhua Pan; Junli Chen; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Ann Transl Med       Date:  2020-02

9.  Early Allograft Dysfunction After Liver Transplantation With Donation After Circulatory Death and Brain Death Grafts: Does the Donor Type Matter?

Authors:  Laura Ioana Mazilescu; Sreelakshmi Kotha; Anand Ghanekar; Leslie Lilly; Trevor W Reichman; Zita Galvin; Mark S Cattral; Mamatha Bhat; Ian D McGilvray; Gonzalo Sapisochin; Blayne Sayed; Markus Selzner; Nazia Selzner
Journal:  Transplant Direct       Date:  2021-07-16

10.  Early Allograft Dysfunction Increases Hospital Associated Costs After Liver Transplantation-A Propensity Score-Matched Analysis.

Authors:  Simon Moosburner; Igor M Sauer; Frank Förster; Thomas Winklmann; Joseph Maria George Vernon Gassner; Paul V Ritschl; Robert Öllinger; Johann Pratschke; Nathanael Raschzok
Journal:  Hepatol Commun       Date:  2020-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.